 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by David Camidge and Erin Schenk.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.149 |
|
|
|
-
Camidge DR, Schenk EL. Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer. Cell. 2020 10 15; 183(2):303-304.
Score: 0.748
-
Ng TL, Johnson A, Nemenoff RA, Hsieh E, Osypuk AA, van Bokhoven A, Li H, Camidge DR, Schenk EL. Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation. J Thorac Oncol. 2021 03; 16(3):486-491.
Score: 0.189
-
Pacheco JM, Camidge DR, Doebele RC, Schenk E. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. Front Oncol. 2019; 9:195.
Score: 0.168
-
Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):e191-e204.
Score: 0.044
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|